634 related articles for article (PubMed ID: 28049011)
1. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
3. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
van der Aa MN; Steyerberg EW; Bangma C; van Rhijn BW; Zwarthoff EC; van der Kwast TH
J Urol; 2010 Jan; 183(1):76-80. PubMed ID: 19913254
[TBL] [Abstract][Full Text] [Related]
4. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
[TBL] [Abstract][Full Text] [Related]
8. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
9. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study.
Roupret M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Sylvester R; Longo F; Montanari E; Palou J
J Urol; 2020 Oct; 204(4):685-690. PubMed ID: 32314931
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence.
Blanca A; Requena MJ; Alvarez J; Cheng L; Montironi R; Raspollini MR; Reymundo C; Lopez-Beltran A
Biomark Med; 2016; 10(3):243-53. PubMed ID: 26861974
[TBL] [Abstract][Full Text] [Related]
12. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
13. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
14. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
15. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.
Koya M; Osborne S; Chemaslé C; Porten S; Schuckman A; Kennedy-Smith A
BMC Urol; 2020 Feb; 20(1):12. PubMed ID: 32046687
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
[TBL] [Abstract][Full Text] [Related]
18. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.
Zuiverloon TC; Tjin SS; Busstra M; Bangma CH; Boevé ER; Zwarthoff EC
J Urol; 2011 Aug; 186(2):707-12. PubMed ID: 21683397
[TBL] [Abstract][Full Text] [Related]
19. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.
Zuiverloon TC; Beukers W; van der Keur KA; Nieuweboer AJ; Reinert T; Dyrskjot L; Orntoft TF; Zwarthoff EC
J Urol; 2013 May; 189(5):1945-51. PubMed ID: 23201384
[TBL] [Abstract][Full Text] [Related]
20. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
de Jong FC; Iflé IG; van der Made AC; Kooper D; de Jong JJ; Franckena M; Zuiverloon TCM; van Criekinge W; Incrocci L; Zwarthoff EC; Boormans JL
Eur Urol Open Sci; 2024 Apr; 62():131-139. PubMed ID: 38496820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
